Eli Lilly wins China approval for first oral GLP-1 weight-loss drug, beating Novo Nordisk
Published 3 d ago2 sourcesEvidence: Reported
A shift toward daily oral diabetes medications could improve access in low-income regions where injectables are impractical. The article highlights potential but lacks specific trial data or regulatory milestones, so the timeline and efficacy remain uncertain. This matters because expanding oral options could reduce diabetes-related mortality and healthcare costs in the Global South.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Published 3 d ago2 sourcesEvidence: Reported
Published 3 d ago2 sourcesEvidence: Reported
Published 3 d ago1 sourceEvidence: Reported
Published 13 h ago1 sourceEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 20 h ago1 sourceEvidence: Reported
Published 1 d ago1 sourceEvidence: Reported
Published 1 d ago1 sourceEvidence: Reported